Intrexon | XON - Equity Capital And Reserves


Intrexon reported $43.17M in Equity Capital and Reserves for its fiscal quarter ending in June of 2024.





Equity Capital And Reserves Change Date
Agenus USD -199.08M 22.15M Jun/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Amgen USD 11.69B 2.5B Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Heron Therapeutics USD 6.91M 2.23M Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
Intrexon USD 43.17M 75.33M Jun/2024
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Ligand Pharmaceuticals USD 967.52M 29.81M Jun/2026
MacroGenics USD 42.87M 21.68M Jun/2026
MannKind USD -67.2M 8M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 32.69B 1.11B Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026
Veracyte USD 1.39B 44M Jun/2026
Xencor USD 503.23M 12.4M Jun/2026